Great Wall Enterprise Co., Ltd.

Minutesfor the 2023 GeneralShareholders Meeting

Time: Friday, 10 a.m. June 16, 2023.

Venue: Auditorium at the Company, No.3, Niaosong 2nd St., Yongkang Dist., Tainan City Chairperson: Chia-Yau Han, the chairman of the board of directors. Recorder: Chia-Lun Lu.

The total shares issued: 894,767,222, Outstanding Shares: 845,707,753,

Total shares represented by shareholders present in person or by proxy: 458,137,170,

(332,663,323 shares exercised via electronic transmission),

Percentage of shares held: 54.17%.

Directors present: Chairman Han Chia-Yau, Director Han Jia-Chen, Director Han

Chia-Yin, Chiao Thai Hsing Investment Company Limited, Representative: Director

Chao Tien-Hsing, Director Wang Zi-Lin, Independent Director Ting Yu-Shan (Chairman

of the Audit Committee), Independent Director Tao Chuang-Chen.

Sit-in Members: Han Fang-Hao (President), Chung Tan-Tan (CPA), Lin Zheng-Xian Attorney). The aggregate shareholding of the shareholders present in person or proxy constituted a quorum. The chairman called the meeting to order.

- A. Chairman's Address (omitted)
- B. Report Items
 - I. 2022 Business Operation
 - II. Audit Committee's Review Report of 2022 Financial Statements
 - III. 2022 Employees' and Directors' Remuneration
 - IV. The Company's Endorsements and Guarantees
 - V. 2022 Cash Dividends Distribution

VI. Others

C. Ratifications

Report 1

proposed by the Board of Director

Subject: To ratify 2022 Financial Statements.

- Description: I. The Company's 2022 parent-only and consolidated financial statements have been audited by Mr. Li Feng-Hui and Ms. Chung Tan-Tan of KPMG.
 - II. The Business Report and the Financial Statements have been reviewed by the Audit Committee.
 - III. The Business Report and the Financial Statements (refer to the appendices).
 - IV. Please ratify the proposal.

Resolution: Voting Result:

1									
Voti	ng Results	% of the total represented							
(including votes	casted electronically)	share present							
Votes in favor	443,177,209votes	96.82%							
Votes against	166,636votes	0.03%							
Votes invalid	Ovotes	0.00%							
Votes abstained / No votes	14,375,449votes	3.14%							

The proposal was approved after voting.

Report 2

proposed by the Board of Director

Subject: To ratify 2022 Profit Distribution.

Description: I. Table of 2022 Distribution of Surplus Earnings was prepared in accordance with Article 34 of the Company's Article of Incorporation, and had been resolved by the Board of Directors and reviewed by the Audit Committee.

III. Please ratify the proposal.

Resolution: Voting Result:

Shares represented at the time of voting: 457,719,294

Voti	ng Results	% of the total represented				
(including votes	casted electronically)	share present				
Votes in favor	443,205,910votes	96.82%				
Votes against	270,440votes	0.05%				
Votes invalid	Ovotes	0.00%				
Votes abstained / No votes	14,242,944votes	3.11%				

The proposal was approved after voting.

D. Special Motion:

There being no other business and special motion, and no motion was raised by shareholders, upon a motion duly made and seconded, the meeting was adjourned.

E. Adjournment.

Appendices

Report to Shareholders

Dear ladies and gentlemen:

Thank you all for participating in this year's annual general meeting, and on behalf of the Company, I would like to express my most sincere gratitude for your persistent support.

In the past two years, having experienced the changes such as the sever COVID-19 pandemic, the insularity policy adopted by various countries around the world, the Brexit, China–United-EU trade dispute, elevation of the trading protectionism, African swine fever, and the Russia-Ukraine War, along with the appreciation of the US dollar due to the continuous rate hikes by the Fed to suppress the inflations in the U.S., the Company has had more frequent changes in the operation, procurements of raw materials, interest rates, and exchange rate hedges; although the prices of bulk cereal increased significantly, but currently, the prices declined again. In terms of the COVID-19 pandemic in Taiwan, in the later half of 2022, the pandemic-containment policies were lifted continuously, the demands for chicken, pork, and edible oil for food and beverage, night markets, and street foods have been elevated gradually. It is expected that the Company's profit will return to the pre-COVID level.

Driven by the mission to uphold business integrity and provide healthy life and safe food for consumers, DaChan Group continues to publish corporate social responsibility report this year. The Company is committed to enforcing traceability for all products sold, and has established its own farm-to-table system. The DaChan Quality Inspection Center not only passes food safety certification of the Ministry of Health and Welfare, but also takes part in the government's Food Safety Alliance Program as a way to raise consumers' confidence in DaChan products.

The Company reported consolidated net operating revenues of NT\$113.3 billion for 2022, up NT\$11.9 billion or 11.69% from 2021; net income attributable to parent company's shareholders amounted to NT\$2.19 billion for 2022, up NT\$0.32 billion or 17.31% from 2021.

All of the Company's factories have passed international and Taiwan's quality and safety certifications, including but not limited to EU HACCP and ISO22000. In addition to having a national grade laboratory featuring the most advanced instruments and systems, the Company also passes food certification of the Ministry of Health and Welfare and completed a modern food processing factory in Machouhou in the end of 2022 that expanded production capacity for precooked frozen foods. Furthermore, the Company has acquired land at Machouhou Industrial Park through tender for phase 2 expansion of food processing capacity as well as the production of plant-based meat. In a

collaboration with Showa Sangyo Co., Ltd. from Japan, a major joint venture is being created for the production of eggs and flour; the factory of modernized auto egg washing and sorting and liquid egg auto storage in Erlin, Changhua will start the production in Q1 2023; it is expected to improve the capacity and enhance the specifications and quality level of the raw eggs, washing and sorting, and liquid egg production. Kouchan Mill Company partnering with Showa has improved the technologies of flour production and formula, and extended the competitive edge from the peers. It is expected to establish the brand image of the Company and enhance the trusts of customers and consumers via the high-level requirements of food safety.

Business Report

I. Report on the 2022 business and financial performance

		Un	it: NTD thousands
Item	2022 - actual	2021 - actual	Variation (%)
Operating revenues	113,297,286	101,437,842	11.69%
Operating profit	3,058,204	2,345,392	30.39%
Profit/loss before tax	3,425,707	2,886,718	18.67%
After-tax EPS	NT\$2.59	NT\$2.21	17.19%

(I) Business performance

(II) Business plan and budget execution

The Company did not make any public financial forecast in 2022, but there was no significant difference between actual operational performance and what the Company had internally planned.

(III) Revenues, expenses, and profitability analysis

(1) Profit and loss

- (a) Interest income amounted to NT\$117,268 thousand in 2022, which were generated from bills and demand deposits.
- (b) Interest expenses amounted to NT\$474,887 thousand in 2022, which had incurred due to short-term and long-term borrowings.

(2) Profitability analysis

Item	2022	2021
Return on assets (%)	5.38%	4.58%
Return on equity (%)	10.06%	8.13%
Operating profit as a percentage of paid-up capital (%)	34.18%	27.52%
Profit before tax as a percentage of paid-up capital (%)	38.29%	33.88%
Net profit margin (%)	2.52%	2.23%
After-tax EPS (NTD)	NT\$2.59	NT\$2.21

(IV) Research and development

DaChan Group continues to increase the level of vertical integration in agricultural and animal food products. Meanwhile, additional efforts are being made to expand into related fields such as: feeds, fats, meats, seafoods, processed foods, biotech, plant-based meat, pet foods, and vaccines. This expanding diversity means that R&D efforts have to be adjusted at the group level to accommodate the Company's future opportunities and market demand, and that more manpower and resources will have to be committed into developing technologies and products that are relevant to the sustainability of the Company's growth.

Sustainability and environmental protection is an issue that modern businesses have to take note of, and besides improving product features, it is also necessary to direct research and development efforts toward the needs of consumers, the environment, and the society as a whole, and contribute to the sustainability of the Earth's environment by addressing waste reduction, carbon reduction, energy conservation, and environmental protection issues.

To ensure ongoing advancement of production technology, the Company not only invests resources and manpower persistently into research and development, the brand new biotech R&D center for food and animal nutrition will start the operation in this year, and continuously expands the testing facilities including: closed-up farm of vaccine-producing eggs, testing farm of poultry, testing farm of pigs, and aquatic producing testing field. Meanwhile, collaborations are being made with local and foreign research institutions such as: National Taiwan University, National Cheng Kung University, National Chung Hsing University, National Pingtung University of Science and Technology, National Taiwan Ocean University, Tainan Livestock Research Institute, Tamsui Animal Health Research Institute, and Schothorst Feed Research to acquire critical technologies and develop application capacity.

II. Summary of 2023 business plan

(I) Operational guidelines

DaChan Group has long specialized in the development of animal and aquaculture feeds, meat products, and restaurant brands. It currently surpasses peers in the market share of compound feeds and electricuted chicken. In addition to pursuing sales growth, the Company places great emphasis on improving feed quality and tightening control over its products, and caters for consumers' health at the source. By venturing into biotechnology, the Company aims to develop biotech products that meet the nutritional requirements of animals in different environments. In terms of egg production, the Company will support the government's policies on washed eggs by adopting total monitoring of feed nutrition, proper egg farm management, regular disease inspection for hens, random inspection of egg quality, and rigorous testing of the final product. With the help of professional cold chain logistics partners, these products will be delivered to customers in the optimal condition. The Company has even established a food development center to oversee research of new machinery, refinement of production process, as well as the development, production, and marketing of plant-based meats. Additionally, the continuously rapid development of the pet food market in the recent years, the Company has decided to invest more resources to the R&D of the pet feed products and market development, while planning to build the brand new pet food production plant, to produce the dry and wet food, snacks, and healthcare product, to develop the product with unique edges and enter the pet market swiftly by utilizing the Group's integrated advantages, as one of the key fields of the Company in the future.

With respect to food processing, the Company's new food processing factory located in Machouhou Industrial Park, Chiayi, commenced mass production at the end of 2022. This modern food processing factory, equipped with multifunctional equipment, performs a wide variety of tasks from frying, roasting, stewing, quality control to automated packaging, and has the capacity to provide local consumers with processed foods of the highest quality and safety.

The Company continues to focus on agricultural and animal products as the main business activity with corporate social responsibilities in mind. Through vertical integration and ongoing improvements to product quality and safety, we strive to raise customers' satisfaction and embrace a brighter future while adhering to our values of integrity and modesty.

(II) Expected sales volume and basis

Based on past performance and changes in market demand, the Company has estimated sales volume for 2023 as follows:

Item	Sales volume (tonnes)
Feeds	3,400,000
Meat (regular + free range chicken)	412,000
Food	210,000
Commodity	1,500,000

(III) Key production/sales policies

In terms of edible oil, DaChan's soybean oil has always bean a trusted brand and preferred product for commercial use, particularly in night markets and food stalls. In terms of the soybean powder, it complements the Company's continuously growing sales of feeds. Regarding the raw material, the stability of the imported soybean is still a great challenge. The arrived soybeans are more than the demand in summers, but in winters, the arrival and demand of soybeans reverse. It is a target for the long-term efforts to maintain the stable domestic supply and demand of oil and powder.

In Taiwan, total deregulation on the import of poultry products combined with slow growth in the demand for animal protein have intensified price competition. As a response, the Company is actively integrating research, development, production, and marketing resources throughout the organization to increase product quality and create differentiation as well as competitive advantage that will lessen the threat of price competition. With the help of animal protein studies from the biotech facility, the Company hopes to provide customers with better quality and safer products that are free of antibiotics.

Regarding the hogs, facing the soaring raw material prices and pressures of hogs' environmental diseases, the Company has worked with the team of ATRI to engage the foreign advisers for coaching the production technologies and practices of hog farms, establishing the management team and the management program of

germplasm, establishing the SOP for the raising and management of hog farm, to improve the raising results and the tracking of the descendant results, so that the performance of sows' reproduction and the hog growth performance are improved for the better overall raising effectiveness and reduced costs of meat production, and the stable profit is made based on the raising and management.

Regarding the native chicken, due to the shortage of chicks and difficulty of chicken shipment resulted from the severe bird flu, the Company has started to sorting the brood hens by weight. It not only improves the rate of spawning, the hens with better quality also reduce the raising costs of chicks. Meanwhile, with the upgraded facilities of the contracted chicken coops, the raising environment is improved for better incubation rate, and the customers are provided with the stable sources of live chicken. The penetration at the major hypermarket channels has been improved gradually, to sale the products under the brand of Dachan Comfort Native Chicken, so that the end customers are able to buy the fresh and healthy native chicken products more conveniently.

The Company has achieved significant success with respect to festive meal and home meal replacement in recent years, particularly with the introduction of new brands such as Yummy Dots. Additional safety inspections and preparation techniques were introduced to food processing to ensure the safety and taste of this new line of products. In light of the fundamental changes in consumers' shopping behaviors, the Company has devoted greater attention into e-commerce besides existing channels; some of its products even managed to top the best-selling chart.

(IV) Future development strategies

1. The Company will continue devoting attention to food safety in light of how consumers local and abroad have become more aware of issues concerning ractopamine, drug residue, the pandemic, and the safety and health of meat and egg products. A food development center has been established to oversee research of existing and new machinery, refinement of production process, as well as the development, production, and marketing of plant-based meats.

In terms of feeds, the Company operates complete yet diversified product lines to minimize business risks, and offers biotech solutions to help customers improve feed efficiency. The Company actively explores vertical integration within the industry as a way to secure advantage and dominance in the supply chain, and is constantly expanding its own ecosystem. After extensive research and development, DaChan is able to make layer feeds, late-stage swine feeds, and late-stage chicken feeds without any antibiotics while achieving zero drug residue. Through introduction of environment-friendly and low pollution feeds for swine and layers, the Company not only promotes productive interactions with the industry, but also strengthens sustainability and competitiveness in feed supply. As for fresh poultry supply, the Company has made extensive vertical integrations from the chicken farm, hatchery, contract farmers, feed suppliers, electrocution slaughterhouse, processing factories all the way to the distribution channels, and markets its own poultry products under the brand - "DaChan Poultry." In doing so, the Company is able to exercise total control in such a way that reduces production cost and ensures the quality and consistency of chicken supply.

With respect to food processing, the Company produces processed poultry goods that can be stored in room temperature, chilled, and frozen, which are distributed nationwide through a variety of channels.

2. The COVID-19 pandemic has fundamentally changed consumers' dining habits. As people become more receptive of cooking at home, they start looking for frozen food options that are easy to store and cook. Satisfying customers' needs to cook and eat at home thus presents a new challenge to food producers, but it also means that there are greater opportunities to innovate.

By incorporating modern production technologies, the Company continually introduces new and differentiated products that taste good and are safe to eat, thereby bringing customers pleasant dining experience with each meal. Changes have also been made to accommodate the smaller dining size per household today; by shifting design emphasis towards smaller volume and greater variety, the Company hopes to appeal to the young population with a new brand image and fresh elements.

Demand for plant-based foods in Asia is expected to grow by 200% over the next five years as vegetarian diet increases in popularity with rising environmental awareness. Having noticed the sizable percentage of vegetarians in Taiwan and the abundant opportunities they represent, the Company has committed significant R&D resources into improving the texture, flavor, and pricing of plant-based meat, as the flavor is what draws consumers to try, while affordability is the key to making plant-based meat popular. Pro-active actions will be taken to expand global market presence in the future.

(V) Impacts of the competitive environment, regulatory environment, and macroeconomic environment

Trade agreements have given rise to several regional markets around the world, allowing goods, services, and information to be delivered free of border limitations. As a result, the Company now faces competition from all over the world. Not only does the Company compete to offer the best product in the global market, it also competes with producers around the world for supply of low-cost materials and services. Faced with such a competitive environment, the Company will play to its size advantage and make bulk purchases worldwide to reduce raw material costs, so that more resources can be directed towards improving product quality and after-sale service.

In light of ongoing food safety issues and consumers' concerns about bird flu

and drug residues in agricultural/animal products, the Company will be making adjustments to the product portfolio while undergoing more extensive upstream-downstream integration to diversify feed risks, and thereby ensure profit stability. DaChan Group remains persistent at promoting safety and traceability for pork, poultry, processed foods, and egg products. Our efforts to ensure "quality and safety" of the food supply chain have been rewarded with favorable results, and we are proud to be able to meet the government's requirements as well as the public's expectations for healthy and safe meats and eggs. By offering 100% assurance, we hope to build DaChan's prestige in the field of food safety and convince consumers of the quality of our products.

Lastly, we wish for your wellbeing and give you our best regards for the future ahead!

Chairman Han Chia-Yau

President Han Fang-Hao

Vice President Liu Chien-Chung

Great Wall Enterprise Co., Ltd. Audit Committee Review Report

The Board of Directors has prepared the Company's 2022 Business Operation Report, Financial Statements and Proposal for Profit Distribution, among which the Financial Statements have been audited by KPMG, Taiwan, by whom an audit report has been issued accordingly. The Business Operation Report, Financial Statements and the proposed profit distribution have been reviewed by us, the Audit Committee of the Company. We have not found any inconsistencies with applicable laws in our review of the aforementioned documents. Therefore, we, the Audit Committee, hereby issue this report in compliance with Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act.

Convener of the Audit Committee: Ting Yu-Shan

Date: March 14, 2023

Independent Auditors' Report

To the Board of Directors of Great Wall Enterprise Co., Ltd.:

Opinion

We have audited the financial statements of Great Wall Enterprise Co., Ltd.("the Company"), which comprise the balance sheets as of December 31, 2022 and 2021, the statements of comprehensive income, changes in equity and cash flows for the years then ended and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audit in accordance with the Regulations Governing Auditing and Certification of Financial Statements by Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Certified Public Accountants Code of Professional Ethics in Republic of China ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition

Regarding the significant accounting policies for revenue recognition, please refer to Note 4(n) and Note 6(v) "Revenue from contracts with customers" from the financial statements.

Description of key audit matter:

Due to the industry characteristics of the Company and following the rules set by competent authorities to announce operating income monthly, revenue recognition timing risk is increased.

How the matter was addressed in our audit:

Our principal audit procedures include:

- Understanding whether the accounting policies and methods for revenue recognition of the audited company are appropriate.

- Testing the Company' s controls and transaction cycle from order to payment regarding revenue recognition
- Performing substantive procedure of revenue, and sampling payments or certified documents for sale transactions
- Selecting the appropriate sample size from the detail in the ending balance of the trade receivable and sending external confirmations to debtors
- Assessing whether revenues are recognized in the appropriate timing

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRSs, IASs, interpretation as well as related guidance endorsed by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the audit committee) are responsible for overseeing the Company' s financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we

exercise professional judgment and professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company' s internal control.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- 4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- 5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 6. Obtain sufficient and appropriate audit evidence regarding the financial information of the investment in other entities accounted for using the equity method to express an opinion on these financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Feng Hui Lee and Tan-Tan Chung.

KPMG

Taipei, Taiwan (Republic of China) March 14, 2023

(English Translation of Financial Statements and Report Originally Issued in Chinese) GREAT WALL ENTERPRISE CO., LTD.

Balance Sheets

December 31, 2022 and 2021

		December 31, 2	<u>)22</u> <u>1</u> %	December 31, 2					ember 31, 21		December 31, 2	
1100	Assets Cash and cas hequivalents (Notes 4 and 6(a))	Amount \$ 253,987		Amount 245,307	<u>%</u> 1	21 XX	Liabilities and Equity Current liabilities:	A	Linio unit	%	Amount	<u>%</u>
1110	Current financial assets at fair value through profit or loss (Note 6(b))	94,473	-	6,912	-	2100	Short-term borrowings (Note 6(m))	\$	9,021,143	25	6,852,626	22
11.50	Notes receivable, net(Notes 4, 6(d) and 7)	1,348,984	4	1,209,731	4	21 10	Short-term notes and bills payable (Note $6(n)$)		3,200,000	9	2,500,000	8
1170	Trade receivable, net(Notes 4, 6(d) and 7)	3,268,776	9	2,889,866	9	21.20	Current financial liabilities at fair value through profit or loss (Note 6(b))		17,895	-	25,046	-
1210	Other receivables due from related parties (Note 7)	1,707,980	5	495,537	2	21.50	Notes payable (Note 7)		442,379	1	282,902	1
130x	Inventories (Notes 4 and 6(e))	2,527,624	7	1,548,198	5	2170	Trade payable (Note 7)		1,588,568	4	886,334	3
1400	Current biological assets (Notes 4 and $\delta(f)$)	1,263,591	3	1,018,984	3	2200	Other payables (Note 7)		1,000,554	3	842,649	3
1410	Prepayments (Note δ(g))	187,572	1	143,114	-	2230	Current income tax liabilities		111,470	-	215,334	1
1476	Other current financial assets	77,921	-	29,624	-	2280	Current lease liabilities (Note 6(0))		47,549	-	46,948	-
1479	Other current assets, others	44,018		113,940		2399	Other current liabilities, others (Note 7)	_	488,522		354,649	1
		10,774,926		7,701,213	24			_	15,918,080	44	12,006,488	39
1517	Non-current financial assets at fair value through other comprehensive	2,249,855	б	2,523,759	8	25XX	Non-Current liabilities:					
	income (Notes 4 and 6(c))					2570	Deferred income tax liabilities (Note $\delta(\mathbf{r})$)		67,713	-	53,314	-
1550	Investments accounted for using equity method (Notes 4 and 6(h))	13,665,289	37	12,624,946	39	2580	Non-current lease liabilities (Note 6(0))		85,172	-	124,550	-
1600	Property, plant and equipment (Notes 4 and 6(i))	8,805,256	24	8,208,556	25	2645	Guarantee deposits received		82,186	-	81,787	-
1755	Right-of-use assets (Notes 4 and $6(j)$)	129,498	-	168,096	1	2670	Other non-current liabilities, others	_	122,195	<u> </u>	122,195	<u> </u>
1760	Investment property, net (Notes 4 and 6(k))	284,813	1	376,150	1			_	357,266	<u> </u>	381,846	
1830	Non-current biological assets (Notes 4 and $\delta(f)$)	348,849	1	296,720	1	2XXX	Total liabilities		16,275,346		12,388,334	39
1840	Deferred income tax assets (Notes 4 and $\delta(\mathbf{r})$)	66,189	-	56,344	-		Equity attributable to owners of parent: (Notes 4 and 6(s))					
1975	Net defined benefit asset, non-current (Notes 4 and 6(q))	119,376	-	108,490	-	3110	Ordinary share		8,947,673	24	8,521,593	26
1990	Other non-current assets, others (Notes 6(1) and 8)	684,170	1	425,813	1	3200	Capital surplus		3,376,370	9	3,294,766	10
		26,353,295	70	24,788,874	76	3300	Retained earnings (Note $\delta(s)$)		7,451,954	20	6,952,880	21
						3400	Other equity interest		1,296,010	4	1,551,646	5
						3500	Treasury shares		(219,132)	<u>(1)</u>	(219,132)	_(1)
					_	3XXX	Total equity	_	<u>20,852,875</u>		20,101,753	61
1XXX	Total assets	\$ <u>37,128,221</u>	<u>100</u> -	32,490,087	100	2-3XX	Total liabilities and equity	\$	37,128,221	100	32,490,087	<u>100</u>

(English Translation of Financial Statements Originally Issued in Chinese) GREAT WALL ENTERPRISE CO., LTD.

Statements of Comprehensive Income

For the years ended December 31, 2022 and 2021

(Expressed in Thousands of New Taiw an Dollars , Except for Earnings Per Common Share)

		2022		2021	
		Amount	%	Amount	%
4000	Operating revenue (Notes 4, $\epsilon(v)$ and 7)	\$ 38,771,998	100	31,612,206	100
5000	Operating costs (Notes 4, 6(e) and 7)	35,659,529	92	27,752,985	88
5900	Gross profit from operations	3,112,469	8	3,859,221	12
6000	Operating expenses:				
6100	Selling expenses	1,410,656	4	1,601,862	5
6200	Administrative expenses	444,456	1	435,761	1
6300	Research and development expenses	106,502	-	101,342	-
64.50	Expected credit impairment loss (Note 6(d))	23,140	_	25,440	
	Total operating expenses	1,984,754	5	2,164,405	6
6900	Net operating income	1,127,715	3	1,694,816	6
7000	Non-operating income and expenses: (Notes 6(w) and 7)				
7100	Interest income	6,910	-	2,942	-
7020	Other gains and losses, net	755,801	2	512,000	2
7050	Finance costs	(211,188)	(1)	(61,289)	-
7070	Share of profit(loss) of associates and joint ventures accounted for using equity method	816,765	2	122,118	
	Total non-operating income and expenses	1,368,288	3	575,771	2
7900	Profit from continuing operations before tax	2,496,003	6	2,270,587	8
7950	Less: Income tax expenses (Note 6(r))	302,942	1	401,202	1
8200	Profit	2,193,061	5	1,869,385	7
8300	Other comprehensive income (loss):				
8310	Items that may not be subsequently reclassified to profit or loss				
8311	Gains (losses) on remeasurements of defined benefit plans	12,379	-	3,164	-
8316	Unsealized gains (losses) from investments in equity instruments	(312,812)	(1)	285,999	1
	measured at fair value through other comprehensive income				
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	2,047	-	633	-
	Items that may not be subsequently reclassified to profit or loss	(302,480)	_(1)	288,530	1
8360	Items that may be subsequently reclassified to profit or loss				
8361	Exchange differences on translation of foreign financial statements	57,176	-	(118,564)	-
8399	Income tax related to components of other comprehensive income				
	that will be reclassified to profit or loss				
	Herns that may be subsequently reclassified to profit or loss	57,176	-	<u>(118,564</u>)	-
8300	Other comprehensive income	(245,304)	<u>(1)</u>	169,966	1
8500	Total conprehensive income	\$ <u>1,947,757</u>	4	2,039,351	8
	Basic earningsper share (Notes 4 and 6(u))				
9750	Basic earnings per share (NT dollars)	\$	2.59		2.21
9850	Diluted earnings per share (NT dollars)	\$	2.59		2.21

(English Translation of Financial Statements Originally Issued in Chinese) GREAT WALL ENTERPRISE CO., LTD.

Statements of Changes in Equity

For the years ended December 31, 2022 and 2021

	Share capital			Retained	eamings			ther equity interes Unrealized gains	t		
	Ordinary shares	Capital surplus	Legal reserve		Unappropriated retained earrings	Total retained earnings	Exchange differences on translation of foreign financial statements	(losses) from financial æsets measured at fair value through other comprehensive income	Total other emity interest	Tieasuryshaies	Total equity
Balance on January 1, 2021	\$ 8,273,391	3,179,626	2,484,061	42,994	5.035.927	7,562,982	(801744)		1,384,211	(219,132)	20,181,078
Profit for the year ended December 31, 2021	-			-	1,869,385	1,869,385					1,869,385
Other comprehensive income for the year ended December 31, 2021					2,531	2,531	(118,564)	285,999	167,435		169,966
Total comprehensive income for the year ended December 31, 2021		· ·			1871916	1,871,916	(118,564)	285,999	167,435		2.p39,351
Appropriation and distribution of retaine d earnings:											
Legal reserve appropriate d			312,376	-	(312,376)	-		-	-	-	
Cash dividends of ordinary share			-		(2,233,816)	(2,233,816)			-	-	(2,233,816)
Stock dividends of ordinary share	248,202		-		(248,202)	(248,202)) -	-	-		
Difference between consideration and carrying amount of subsidiaries acquired or disposed	-	(7,339)		-	-	•	-	-			(7,339)
Adjustment of capital surplus for company's cash dividends received by		122,479									122,479
subsidiaries											
Balance on December 31,2021	8,521,593	3,294,766	2,796,437	42,994	4,113,449	6,952,880	(920,308)	2,471,954	1,551,646	(219,132)	20,101,753
Profit for the year ended December 31, 2022				- 1	2,193,061	2,193,p61					2 Î 93 D61
Other comprehensive income for the year ended December 31, 2022			-	-	10,332	10,332	57,176	(312,812)	(255,636)		(245,304)
Total comprehensive income for the year ended December 31, 2022					2,203,393	2,203,393	57,176	(312,812)	(255,636)		1947,757
Appropriation and distribution of retained earnings:											
Legalreserve appropriate d			187,191		(187,191)	-			-	-	
Cash dividends of ordinary share			-	-	(1,278,239)	(1,278,239)			-		(1,278,239)
Stock dividends of ordinary share	426,080	-	-	-	(426 ₀ 80)	(426,080)) -	-	-	-	-
Difference between consideration and carrying amount of subsidiaries acquired or disposed		11,519			-			-			11,519
Adjustment of capital surplus for company's cash dividends received by subsidiaries		70,085		-	-			-			70,085
Balance on December 31, 2022	\$ 8,947,673	3,376,370	2,983,628	42,994	4,425,332	7,451,954	(863,132)	2,159,142	1,296,010	(219,132)	20,852,875

(English Translation of Einancial Statements and Report Originally Issuel in Chinese) GREA TWALL ENTERPRISE CO., LTD.

Statements of Cash Flows

For the years ended December 31, 2022 and 2021

Cah flows from operating artivities: 1 Profit before tax \$ 2,496,003 Adjustments: 605,573 Depreciation expense 605,573 Specied credit inpaim ent loss 10,563 Expected credit inpaim ent loss 23,140 Difficient inpaim ent loss 23,140 Interest expense 10,563 Interest expense 211,188 Interest expense (6,910) Difficient inpaim ent loss (94,712) Charge in order property plant and equipm ent (5958) Charges in networking assets and liabilities (134,233
Adjustments:Adjustments:Adjustments:Adjustments:Adjustments:Control of the set of the
Adjustments to reconcile profit (005):Deprecintion expense605,573526,016Am artisztin expense10,56317,298Bepeted credit in paim ert los23,14025,440Net (gain) loss an financial assets or liabilities atfair value throughprofit or loss(94,712)15,289Interest expense211,18861,289Interest income(6,910)(2,942)Dividend income(98,295)(96,004)Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity(816,765)(122,118)method(5,958)(3,942)(1,007)(2,902)Orange infair value of biological assets(1,107)(2,202)Total adjustments to reconcile profit (loss)(173,283)418,224Changes in notescrecirable(139,253)(348,108)Increase in trate receirable(139,253)(348,108)Increase in inventories(979,456)119,276Increase in thiological assets(68,915)(35,194)Increase in the current assets(68,915)(35,194)Increase in the current assets(68,915)(35,194)Increase in the current assets(1,337)(1,737)Increase in the current assets(633)(673)Increase in the psynble(1,377)(1,739)Increase in the psynble(19,477)232,533Increase in the psynble(19,477)232,533Increase in the psynble(13,464)(44,029)Increase in other psynble(13,464)(44,029)
Depreciation expense605,573526,016Am artization expense10,56317,898Expected credit inpaiment loss23,14025,440Net(gain) loss on finamical assets or liabilities atfair value throughprofil or loss(94,712)15,389Interest expense211,18861,289Interest income(6910)(2,942)Diriched income(98,395)(96,004)Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity(816,765)(122,118)method(1,007)(2,902)(1,007)(2,902)Total adjustments to reconcile profit (loss)(173,383)418,524Changes in questing assets and liabilities:(139,253)(348,108)Increase in tract exceivable(139,253)(348,108)Increase in tract exceivable(129,5629)(191,238)Increase in tract exceivable(295,629)(191,238)Increase in tract exceivable(130,276)(32,549)Increase in the correst extrement excercitable(13,577)(32,549)Increase in the correst extrement ex
Amortization experse 10,563 17,598 Expected credit impairment loss 23,140 22,440 Net (gain) loss on financial assets or liabilities atfair value throughprofit or loss (34,712) 15,389 Interest expense 211,188 61,289 Interest expense (6,910) (2,942) Dirikind income (98,995) (96,004) Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity (816,765) (122,118) method (11,000) (2,902) (2,902) Chan on disposal of property, plant and equipment (5,958) (3,942) Changes in operating assets and liabilities: (11,000) (2,902) Total aljustments to reconcile profit (loss) (172,533) 418,234 Changes in notes receivable (130,233) (348,108) Increase in intractories (290,022) (191,238) Increase in intractories (291,022) (192,233) Increase in intractories (292,022) (192,233) Increase in intertories (292,022) (112,233) Increase in intertories (129,022) (129,022) Increase in interto
Nkt (gain) loss on financial assets or liabilities at fair value throughprofit or loss (94,712) 15,389 Interest expense 211,188 61,289 Interest income (6,910) (2,242) Dividend income (98,295) (96,010) (22,421) Dividend income (98,295) (96,010) (122,118) method (98,295) (91,010) (2,202) Total aljustments to reconcile profit (loss) (173,383) 418,524 Changes in operating assets and liabilities: (139,253) (348,108) Increase in interscriptible (130,253) (348,108) Increase in interscriptible (130,256
Interest spense211,18861,289Interest income(6,910)(2,942)Dividend income(98,995)(96,004)Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity(816,765)(122,118)method(5,958)(5,958)(3,942)Change infair value of biological assets(1,107)(2,902)Total adjustments to reconcile profit (loss)(173,283)418,524Changes in questing assets and liabilities:(139,253)(348,108)Increase in integrace instructore instance(979,426)130,276Increase in trade receivable(129,629)(191,228)Increase in biological assets(295,629)(191,228)Increase in integraph ets(63,915)(32,5194)Decrease in interproph ets(63)(67)Increase in deferred debits(139,271)(5,799)Increase in integraph bl(139,273)(348,108)Increase in deferred debits(1337)(5,799)Increase in deferred debits(63)(67)Increase in deferred debits(63)(67)Increase in integraph bl119,477232,533Increase in integraph bl119,477232,533Increase in integraph bl113,64449,442Increase (increase) in other current liabilities77,364(44,099)
Interest informe (6,910) (2,942) Dividend income (98,995) (96,004) Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity (816,765) (122,118) method (5,958) (3,942) (1,007) (2,902) Total algustments to reconcile profit (loss) (173,383) 418,524 Changes in operating assets and liabilities: (139,233) (348,108) Increase in interserceitable (139,233) (348,108) Increase in trade receitable (199,426) 130,276 Increase in biological assets (295,632) (191,238) Increase in biological assets (295,632) (191,238) Increase in biological assets (295,632) (191,238) Increase in invertories (295,632) (191,238) Increase in trade receitable (133,77) (5,799) Increase in other current assets (68,915) (35,194) Increase in deferred debits (653) (67) Increase in deferred debits (653) (67) Increase in other psynble 119,447
Dividend income(98,295)(96,004)Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity method(816,765)(122,118)Gain on diposal of property, plant and equipment Charge in fair value of biological assets(1,007)(2,202)Total adjustments to reconcile profit (loss)(173,233)418,524Charges in operating assets and liabilities: Increase in notes receivable(139,253)(348,108)Increase in trade receivable(139,253)(348,108)Increase in trade receivable(139,253)(144,226)(Increase) Decrease in invertories(979,426)150,278)Increase in biological assets(295,629)(191,238)Increase in trade receivable(139,273)(348,108)Increase in biological assets(295,629)(191,238)Increase in biological assets(295,629)(191,238)Increase in trade receivable(139,271)(32,594)Increase in trade receivable(139,273)(348,108)Increase in biological assets(295,629)(191,238)Increase in trade receivable(295,629)(191,238)Increase in other financial assets(1,377)(5,799)Increase in other financial assets(633)(67)Increase in deferred debits(633)(67)Increase in deferred debits199,477252,523Increase in other psyable113,46449,442Increase (decrease) in other current liabilities77,364(44,099)
Share of (profit) loss of subsidiaries, associates and joint ventures accounted for using equity method(\$16,765)(122,118)Gain on disposal of property, plant and equipment Charge infair value of biological assets(5,958)(3,942)Total adjustments to reconcile profit (loss)(1,107)(2,202)Total adjustments to reconcile profit (loss)(173,333)418,524Charges in operating assets and liabilities: Increase in notes receivable(139,253)(348,108)Increase in trade receivable(139,253)(348,108)Increase in trade receivable(400,000)(474,226)(Increase) Decrease in invertories(979,426)190,276Increase in biological assets(295,629)(191,238)Increase in biological assets(295,629)(191,238)Increase in other current assets(633)(67)Increase in deferred debits(1337)(5,799)Increase in other physible199,477252,533Increase in other physible113,46449,442Increase (decrease) in other current liabilities77,364(44,099)
method(5,958)(3,942)Change intrivulue of biologicalasets(1,107)(2,502)Total aljustments to reconcile profit (loss)(173,383)418,524Changes in operating assets and lisbilities: Increase in interspeciable(139,253)(348,108)Increase in trade receivable(402,000)(474,226)(Increase) Decrease in interspeciable(2979,426)(190,276)Increase in trade receivable(2979,426)(191,280)Increase in trade receivable(2979,426)(191,280)Increase in biologicalasets(2979,426)(191,280)Increase in trade receivable(2979,426)(191,280)Increase in trade receivable(295,629)(191,280)Increase in trade receivable(295,629)(191,280)Increase in trade receivable(295,629)(191,280)Increase in trade receivable(295,629)(191,280)Increase in trade receivable(1337)(5,790)Increase in other financial assets(1337)(5,790)Increase in deferred debits(653)(671)Increase in other psyable199,477223,533Increase (decrease) in trade psyable113,46449,442Increase (decrease) in other current liabilities77,364(44,099)
Gain on disposal of property, plott and equipment. Change infair value of biological assets Total adjustments to reconcile profit (loss) (5,958) (1,107) (2,902) (2,902) Total adjustments to reconcile profit (loss) (173,383) 418,524 Changes in operating assets and liabilities: Increase in notes receivable (139,253) (348,108) Increase in invertories (402,000) (474,226) (Increase) Decrease in invertories (979,436) 130,276 Increase in trade receivable (295,629) (191,238) Increase in the corrent assets (68,915) (33,194) Increase in other corrent assets (633) (67) Increase in deferred debits (653) (67) Increase in other physible 139,477 232,533 Increase in other physible 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Charge infair value of biological assets (1,107) (2,202) Total adjustments to reconcile profit (loss) (173,383) 418,524 Charges in operating assets and liabilities: (139,253) (348,108) Increase in nuclescreceitable (402,000) (474,226) (Increase) Decrease in invertories (979,426) 150,276 Increase in truck receitable (295,629) (191,238) Increase in other current assets (68,915) (35,194) Increase in other firminal assets (1,337) (5,739) Increase in other physible (139,477) 252,533 Increase (decrease) in other current liabilities 702,224 (597,211) Increase (decrease) in other current liabilities 77,364 (44,099)
Changes in operating assets and liabilities: (139,253) (348,108) Increase innotes receivable (402,000) (474,226) (Increase) Decrease inivertories (979,426) 130,253) Increase in biologial assets (295,620) (191,238) Increase in biologial assets (295,620) (191,238) Increase in prepryments (44,457) (32,549) Decrease (increase) in other current assets 68,915 (35,194) Increase in deferred debits (139,273) (5,799) Increase in interprymease (653) (67) Increase in other physicle 199,477 252,579 Increase in other physicle 702,224 (597,211) Increase in other physicle 113,464 49,4409 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in notes receivable (139,253) (348,108) Increase in trade receivable (402,030) (474,226) (Increase) Decrease in inventories (979,426) 150,276 Increase in biological assets (295,629) (191,238) Increase in prepayments (295,629) (191,238) Decrease (increase) in other current assets (68,915) (35,194) Increase in other financial assets (1,337) (5,799) Increase in other financial assets (653) (67) Increase in other physible 159,477 252,523 Increase in other physible 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in trade receitable (402,030) (474,226) (Increase) Decrease in interactories (979,436) 130,276 Increase in biological assets (295,629) (191,238) Increase in prepayments (44,457) (33,194) Decrease (increase) in other current assets 68,915 (35,194) Increase in deferred debits (1,337) (5,739) Increase in other physical assets (653) (67) Increase in other physical assets (1,337) (5,739) Increase in other physical assets (1,337) (29,733) Increase in other physical assets (653) (67) Increase in other physical assets 139,477 232,533 Increase in other physical assets 702,234 (597,211) Increase in other physical assets 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
(Increase) Decrease in invertories (979,426) 190,276' Increase in biological assets (295,629) (191,238) Increase in prepayments (244,457) (32,549) Decrease (increase) in other current assets (68,915 (35,194) Increase in other financial assets (1,337) (5,759) Increase in other financial assets (653) (67) Increase in other payable 159,477 252,533 Increase in other payable 1702,224 (597,211) Increase in other payable 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in biological assets (295,629) (191,238) Increase in prepayments (44,457) (32,549) Decrease (increase) in other current assets (68,915 (35,194) Increase in other financial assets (1,337) (5,759) Increase in other financial assets (653) (67) Increase in other payable 159,477 252,533 Increase in other payable 702,224 (597,211) Increase in other payable 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in prepayments (44,457) (32,549) Decrease (increase) in other current assets 68,915 (35,194) Increase in other financial assets (1,337) (5,739) Increase in deferred debits (653) (67) Increase in interespayable 159,477 252,533 Increase (decrease) in trade payable 702,224 (597,211) Increase (decrease) in other current liabilities 77,364 (44,099)
Decrease (inrease) in other current assets 68,915 (35,194) Increase in other financial assets (1,337) (5,739) Increase in deferred debits (653) (67) Increase in notes payable 159,477 252,533 Increase (decrease) in trade payable 702,234 (597,211) Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in other financial assets (1,337) (5,739) Increase in deferred debits (653) (67) Increase in notes payable 159,477 252,533 Increase (decrease) in trade payable 702,234 (597,211) Increase (decrease) in other payable 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in notes payable 1.90,477 2.52,533 Increase (decrease) in trade payable 702,234 (597,211) Increase in other payable 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase (decrease) in trade payable 702,234 (597,211) Increase in other payable 113,464 49,442 Increase (decrease) in other current liabilities 77,364 (44,099)
Increase in other physical 113,464 49,442 Increase (decrease) in other current liabilities
Increase (decrease) in other current liabilities
Total adjustments (914.954) (857.676)
Cash inflow generated from operations 1,581,049 1,412,911
hterest.received 7,918 2,942
Interest paid (166,748) (46,148)
Income taxes paid (404,299) (463,830) Net each flows from operating activities 1,017,930 905,875
Cah flow used in investing activities:
Acquisitant investments accounted for using equitymethod (200,000) (626,618)
Proceeds from capital neduction of financial assets at fair value through other comprehensive income 4,107
Acquisition of property, plant and equipment (1,072,491) (1,271,476)
Proceeds from disposal of property, plant and equipment 13,528 11,542
(Increase) decrease in other receivables due from related parties (1,212,443) 116,691
Increase in other nan-concent assets (268,920) (136,64.5) Dividends received 175,988 133,967
Net cash flows used in investing artivities (2610.231) (1,732,539)
Cash flows from (used in) financing activities :
Increase in short-term bins 2,168,517 2,214,220
Increase in short-term potes and bills payable 700,000 800,000
Intrease in guarantee deposits received 399 5,997
Payment of lease liabilities (46,196) (44,945) Increase in other non-current liabilities 56,510 60,000
Increase in other non-current liabilities 56,510 60,000 Cash diridends paid(1278,239)(2233,816)
Net cash flows from financing activities 1600,991 801,436
Netincrease (decrease) in cash and cash equivalents 8,600 (45,208)
Cash and cash equivalents at beginning of period 245,307 290,515
Cash and cash equivalents at end of period <u>\$253.967</u> 245.307

Independent Auditors' Report

To the Board of Directors of Great Wall Enterprise Co., Ltd.:

Opinion

We have audited the consolidated financial statements of Great Wall Enterprise Co., Ltd. and its subsidiaries ("the Group"), which comprise the consolidated balance sheets as of December 31, 2022 and 2021, the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2022 and 2021, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the International Financial Reporting Standards ("IFRSs"), International Accounting Standards ("IASs"), Interpretations developed by the International Financial Reporting Interpretations Committee ("IFRIC") or the former Standing Interpretations Committee ("SIC") endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Account of Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition

Please refer to Note 4(p) and Note 6(aa) "Revenue from contracts with customers" from the financial statements.

Description of key audit matter: Due to the industry characteristics of the Company and following the rules set by competent authorities to announce operating income monthly, revenue recognition timing risk is increased.

Our principal audit procedures include:

- Understanding whether the accounting policies and methods for revenue recognition of the audited company are appropriate

- Testing the Company' s controls and transaction cycle from order to payment regarding revenue recognition
- Performing substantive procedure of revenue, and sampling payments or certified documents for sale transactions
- Selecting the appropriate sample size from the detail in the ending balance of the trade receivable and sending external confirmations to debtors
- Assessing whether revenues are recognized in the appropriate timing

Other Matter

Great Wall Enterprise Co., Ltd. has additionally prepared its parent-company-only financial statements as of and for the years ended December 31, 2022 and 2021, on which we have issued an unmodified opinion.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRSs, IASs, interpretation as well as related guidance endorsed by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the audit committee) are responsible for overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor' s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group' s internal control.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- 4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- 5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 6. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Feng Hui Lee and Tan-Tan Chung.

KPMG

Taipei, Taiwan (Republic of China) March 14, 2023

(English Translation of Consolidated Financial Statements and Report Originally Issued in Chinese) GREAT WALL ENTERPRISE CO., LTD. AND SUBSIDIARIES

Consolidated Balance Sheets

December 31, 2022 and 2021

		December 3		December 31, 2					022	December 31, 2	:021
llxx	Assets Current assets:	Amount	%	Amount	<u>%</u>	21 xx	Liabilities and Equity Current liabilities:	Amount		Amount	%
1100	Cash and cash equivalents (Notes 4 and 6(a))	\$ 5,145,6	91 8	6,083,001	11	2100	Short-term borrowings (Notes 4 and 6(p))	\$ 15,153,347	24	13,183,124	23
1110	Current financial as sets at fair value through profit or loss (Note $\delta(b)$)	94,7		7,705	_	21100	Short-term notes and bills payable (Notes 4 and 6(q))	3,660,000	6	2,914,931	5
11.50	Notes receivable, net (Notes 4, 6(d) and 7)	1,691,2		1,582,488	3	2120	Current financial liabilities at fair value through profit or loss (Notes 4 and	20,150		27,315	
1170	Trade receivables (Notes 6(d) and 7)	6,816,3		5,952,083	10	2120	6(b))	20,100		27472	
130x	Inventories (Notes 4 and 6(e))	10,901,3		8,176,015	14	21.50	Notes payable (Note 7)	385,060	1	695,453	1
1400	Current biological assets, net (Note 6(f))	2,233,8		1,803,467	3	2170	Trade payables (Note 7)	6,118,449	10	5,246,498	9
1410	Prepayments (Note 6(g))	1,798,0		1,450,708	3	2200	Other payables (Notes 4, 6(s) and 7)	2,666,878	4	2,364,368	4
1476	Other current financial assets (Note (h))	372,2	56 1	303,641	1	2230	Current income tax liabilities (Note 4)	273,684	-	318,261	1
1479	Other current assets, others	891,3	49 1	1,236,656	2	2280	Lease liabilities (Notes 4 and 6(t))	188,329	-	191,053	-
		29,945,0	74 48	26,595,764	47	2320	Long-term liabilities, current portion (Notes 4 and $\delta(\mathbf{r})$)	109,354	-	185,336	-
15xx	Non-current æsets:					2399	Other current liabilities, others (Note 7)	1,904,470	3	1,451,890	3
1517	Non-current financial assets at fair value through other comprehensive	2,617,7	31 4	2,933,887	5			30,479,721	48	26,578,229	46
	income (Notes 4 and $\delta(c)$)					25xx	Non-Current liabilities:				
1550	Investments accounted for using equity method, net (Notes 4 and $\delta(j)$)	1,744,1		1,741,218	3	2540	Long-term borrowings (Notes 4 and 6(r))	1,739,633	3	1,153,218	2
1600	Property, plant and equipment (Notes 4 and 6(1))	22,235,6	11 36	20,290,137	36	2551	Non-current provisions for employee benefits (Notes 4 and $\epsilon(v)$)	3,439	-	4,930	-
1755	Right-of-use assets (Notes 4 and 6(m))	1,912,7	22 3	1,993,146	4	2570	Deferred income tax liabilities (Notes 4 and 6(w))	108,069	-	85,486	-
1760	Investment property, net (Notes 4 and $\delta(n)$)	656,3	41 1	692,850	1	2580	Lease liabilities non-current (Notes 4 and $6(t)$)	869,445	1	929,787	2
1805	Goodwill	150,2	67 -	158,024	-	2645	Guarantee deposits received	89,134	-	90,603	-
1830	Non-current biological assets (Notes 4 and $\delta(\mathbf{f})$)	591,6	24 1	614,240	1	2670	Other non-current liabilities, others	155,854		150,268	
1840	Deferred income tax assets (Note 4)	260,0	83 -	193,452	-			2,965,574	4	2,414,292	4
1975	Net defined benefit asset, non-current (Notes 4 and 6(v))	1 19,3	76 -	108,490	-	2ххх	Total liabilities	33,445,295		28,992,521	_50
1990	Other non-current assets, others (Notes 6(0) and 8)	2,108,5	<u>23 4</u>	1,410,922	3		Equity attributable to owners of parent (Notes 4 and 6(x)):				
		32,396,4	47 52	30,136,366	53	3100	Capital stock	8,947,673	14	8,521,593	15
						3200	Capital surplus	3,376,370	6	3,294,766	6
						3300	Retained earnings	7,451,954	13	6,952,880	12
						3400	Other equity interest	1,296,010	2	1,551,646	3
						3500	Treasury shares	(219,132)) ((219,132)	· ·
							Total equity attributable to owners of parent:	20,852,875	35	20,101,753	36
						36xx	Non-controlling interests (Notes 4 and $\delta(i)$)	8,043,351	13	7,637,856	14
						Зжжк	Total equity	28,896,226	48	27,739,609	50
lxxx	Total assets	\$ <u>62,341,5</u>	<u>21 100</u>	56,732,130	100	2-3жж	Total liabilities and equity	\$ <u>62,341,521</u>	<u>100</u>	56,732,130	<u>100</u>

(English Trens lation of Consolidated Financial Statements Originally Issued in Chinese) GREAT WALL EN TERPRISE CO., LTD. AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

For the years ended December 31,2022 and 2021

(Expressed in Thousands of New Taiwan Dollars , Except for Earnings Per Common Share)

		20 22		20 21	
		Amount	96	Amount	96
4000	Operating measure (Notes 4, 4(aa) and 7)	\$113,297,284	100	101,437,842	100
5000	Operating costs (No tes 4, 4(a) and 7)	101,938,514	90	90,701,292	_ 89
5900	Grossprofit (loss) from operations	11,358,770	10	10,734,550	
6000	Operating expenses:				
\$100	Sa Ilin gan pansas	5,605,608	5	5,648,032	6
\$200	Adminis tratine sepanses	2,503,240	2	2,354,485	3
6300	Research and development expenses	1 51,987	-	138,290	-
64.50	Expacted and it loss (Notes + and 4(d))	39,731	-	248,351	<u> </u>
	Total op ersting expenses	8,300,566	7	8,391,158	9
6900	Net operating in come (loss)	3,0 58,204	3	2,345,392	2
7000	Non-operating income and expenses: (Notes 6(ab) and 7)				
7100	Interstincome	117,248	-	84,153	-
7020	Other gains and losses, net	755,705	1	733,410	1
7050	Finance cost	(4.74,887.)	-	(284,423)	-
7040	Sham of profit (loss) of a sociates and joint ventures accounted for using equity method, net	(30,583.)	<u> </u>	6,186	<u> </u>
	Tote In on-operating in come and expenses	3 67,503		541.324	
7900	Profit (loss) from continuing operations before tax	3,425,707	+	2,884,718	3
7950	Less: Incomentax expenses (Notes 4 and 6(w))	5 75,581		624,695	
8200	Profit (loss)	2.850.124	3	2.242.023	2
8300	Other comprehensive in come:				
8310	Components of other comprehensive in come that will not be reclassified to profit or loss				
8311	Gains (losses) on measurements of datined benefit plans	12,393	-	3,144	-
8314	Unnedised gains (losses) for minuserments in equity instruments mass used at fair value through other comprehensive income	Ģ12,812)	•	285,999	
8349	Less: Income tax alsted to components of other comparisons income that will not be melassified to profit or loss	2,047	<u> </u>	- 633	<u> </u>
	Components of other comprehensive income that will not be malassified to profit or loss	(302,444)	<u> </u>	288,530	<u> </u>
8340	Components of other comprehensive in come (loss) that will be reclassified to profit or loss				
8341	Exchange differences on translation of foreign financial statements	97,478	-	(204,872)	-
8399	Less: Income tax maked to components of other companiencine income that will be males sified to profit or less		<u> </u>		<u> </u>
	Components of other companies income that will be achesified to public to be	97,478	<u> </u>	(204,872)	<u> </u>
8300	Other comprehensive in come	(204,788)	<u> </u>	83,638	<u> </u>
	Total comprehensive income	\$ <u>2,645,338</u>	3	2,345,681	
	Profit (loss) ettributeb loto:				
	Profit (loss) attributable to owners of parent	\$ 2,193,041	2	1,849,385	2
	Pm fit(loss) attributable to non-controlling interest	657,065	1	392,438	<u> </u>
		\$ <u>2,850,126</u>	3	2,262,023	2
	Comprehensive in come attributebleto:				
	Computancing income, attributable to owners of paramet	\$ 1,947,737	3	2,039,351	2
	Compalancia incoma attributable to non-contro lling intens t	(97,581	1	304,330	
	- •	\$ 2,645,338	4	2,345,681	2
	Besic eem ings pershere (Note 6(x))				_
	Baic saming per chan (Unit. NID)	\$	2.59		2 21
	Diluted samin 5 per chan (Unit: NID)	\$	2 59		2 21
_					

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) GREAT WALL ENTERPRISE CO., LTD. AND SUBSIDIARIES

Consolid ated Statements of Changes in Equity

For the years ended December 31, 2022 and 2021

					Equity attrib	utable to owners	ofparent						
							Total	l other equity into	eæst				
						-		Unrealized					
	Share capital			Retained	learnings			gains					
		_						(losses) on					
							Exchange	financial assets					
							differences on	measured at					
							translation of	fair value			Total equity		
					Unappropriated		foreign	through other			attributable to	Non-	
	Ordinary	Capital	Legal	Special	retained	Total retained	financial	comprehensive	Total other	Treasury	owners of	controlling	
	~		-	-									T 1 1
Balance at January 1, 2021	shares \$ 8,273,391	<u>surplus</u> 3,179,626	2,484,061	reserve 42,994	eamings 5035927	eamings 7,562,982	statements (801,744)		equity interest 1384 211	<u>shares</u> (219,132)	<u>parent</u> 20,181,078	interests 7,705,674	<u>Total equity</u> 27,886,752
Profit (loss)	φ <u>ο</u> ξεί <u>δο</u> φ	5,1/9,020	2,904,001	42,994	1869385	1,869,385	(001/44)2,103,233	1204211	(219452)	1,869,385	392,638	2,262,023
Other comprehensive income			-		2,531	2,31	(118,564))285,999	167,435		169,966	(86,308)	83,658
Total comprehensive income	<u> </u>				1871916	1,871,916	(118,564)	285.999	167 435		2.039.351	306 330	2,345,681
Appropriation and distribution of retained earnings:					10/10/10	1,0/1,010	(110,004)	107,900		2,00,01		2040001
Legalreserve appropriate d			312376		(312,376)								
Stock dividends of ordinary share	248,202				(248,202)								
Cash dividends of preference share	-				(2,233,816)						(2,233,816)		(2,233,816)
Other changes in capital surplus:					<- <i>FF</i> /	</td <td></td> <td></td> <td></td> <td></td> <td>(-,,/</td> <td></td> <td>·/</td>					(-,,/		·/
Adjustments of capital surplus for company's cash dividends		122,479			-						122,479		122,479
received by subsidiaries		,											<i>,</i>
Difference between consideration and carrying amount of		(7,339)	-		-	-	-	-	-	-	(7,339)		(7,339)
subsidiaries acquired or disposed													
Changes in non-controlling interests	<u> </u>		<u> </u>			<u> </u>	<u> </u>		<u> </u>	<u> </u>	<u> </u>	(374,148)	(374,148)
Balance at December 31, 2021	8,521,593	3,294,766	2,796,437	42,994	4,113,449	6,952,880	(920,308)) 2,471,954	1,551,646	(219,132)	20,101,753	7 £37 £56	27,739,609
Profit (loss)			-		2,193,061	2,193,061	-	-	-	-	2,193,061	657 £65	2,850,126
Other comprehensive income	·		<u> </u>		10,332	10,332	57,176	(312,812)	<u>(255.636</u>)	<u> </u>	(245,304)		(204,788)
Total comprehensive income	<u> </u>	·	<u> </u>		2,203,393	2,203,393	57,176	(312,812)	<u>(255.636</u>)	<u> </u>	1,947,757	697,581	2¢45,338
Appropriation and distribution of retaine d earnings:			187,191		(102.101)								
Legalreserve appropriate d Cash dividends of ordinary share			18/191	-	(187,191) (1,278,239)			-			(1,278,239)		(1,278,239)
Stock dividends of ordinary share	426,080	-	-	-	(426,080)			-	-	-	(966,00,000)		(لادغرہ/مر1)
Difference between consideration and carrying amount of	420,000	11,519		-	(420,000)	(420,000)					11,519		11,519
subsidiaries acquired or disposed		11,019	-		-	-	-	-			11,019		11,019
Cash dividends received by subsidiaries due to holding the		70,085									70,085		70,085
parent company's stocks		.0,000									,0,000		.0,000
Changes in non-controlling interests												(292,086)	(292,086)
Balance at December 31, 2022	\$ 8,947,673	3,376,370	2,983,628	42,994	4,425,332	7,451,954	(863,132)	2,159,142	1,296,010	(219,132)	20,852,875	8,043,351	28,896,226

(English Translation of Consolidated Financial Statements and Report Originally Issued in Chinese) GREAT WALL ENTERPRISE CO., LTD. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the years ended December 31, 2022 and 2021

	 2022	2021
Cash flows from (used in) operating activities :		
Profit before tax	\$ 3,425,707	2,886,718
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expense	2,104,938	1,886,549
An artization expense	30,542	46,465
Epected credit loss	39,731	248,351
Net (gain) loss an financial assets or liabilities at fair value through profit or loss	(94,239)	17,660
hterest expense	474,887	284,623
hterest income	(117, 268)	(86,133)
Dividend income	(114,571)	(111,467)
Share of loss (profit) of associates and joint ventures accounted for using equitymethod	30, <i>5</i> 83	(6,186)
Gain an disposal of property, plant and equipment.	(2,763)	(55,694)
Impairment loss on goodwall	20,846	-
Inpain ent (reversal gain) loss on property, plant and equipment	(29,231)	167,538
White down of inventory (Reversal of varite-down)	1,425	(383)
Loss on disposal of inventory	45,527	12,521
Changes in fair value of biological assets	 329,832	(37,485)
Total adjustments to reconcile profit	 2.720.239	2366.339
Changes in operating assets and Itabilities:		
Intrease in notes receivable	(108,780)	(474,926)
Imrease in accounts receivable	(904,022)	(974,454)
Increase in inventories	(2,772,334)	(39,821)
Changes in biological assets	(692,560)	(349,023)
Increase in prepayments	(347,376)	(532,319)
Decrease (increase) in other current assets	345,307	(152,979)
(Increase) decrease in other financial assets	(68,615)	498,606
(Decrease) increase in notes payable	(310,393)	476,330
Intrease in accounts payable	871,950	730,284
Increase in other payable	266,475	145,070
Increase (decrease) in other current liabilities	4.52,580	(151,007)
Increase in net defined benefit, liability	 8,854	329
Total changes in operating assets and liabilities	 (3.258.914)	(823.910)
Total adjustments	 (538,675)	1,542,429
Cash inflow generated from operations	2,887,032	4,429,147
Interest received	117,268	86,133
Income taxes paid	 (664,206)	(233,632)
Net cash flows from operating activities	2,340,094	4,281,668
Cash flows from (used in) investing activities:		
Increase in prepayments for investments	4,107	-
Acquisition of property, plant and equipment.	(3,876,976)	(3,177,620)
Proceeds from disposal of property, plant and equipment.	286,166	175,308
Decrease in other non-coment assets	(739,030)	(415,741)
Dividends received	 114.571	111.467
Net cash flows used in investing activities	 (4,211,162)	(3,306,586)

(English Translation of Consolidated Financial Statements and Report Originally Ested in Chinese) GREAT WALL ENTERPRISE CO., LTD. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the years ended December 31, 2022 and 2021

	2022	2021
Cash flows used in financing artivities:		
Increase in short-term loons	94,250,554	62,043,332
Decrease in short-term loans	(92,616,931)	(57,713,575)
Increase in short-term notes and bills payable	30,226,069	22,293,000
Decrease in short-term notes and bills payable	(29,481,000)	(21,365,000)
Proceeds fram lang-term debt.	1,300,455	2,088,309
Repryments of long-term debt.	(863,876)	(2,971,552)
(Decrease) increase in guarantee deposits received.	(1,469)	7,271
Payment of lease liabilities	(207,809)	(184,776)
Cash dividendspaid	(1,208,154)	(2,111,337)
hterstpaid	(438,852)	(272,755)
Change innon-controlling interests	(292,086)	(374,148)
Net cash flows from financing a divides	666,901	1,438,769
Rifect of exchangerate changes on cash and cash equivalents	266,857	(819,336)
Net (decrease) increase in cash and cash equivalents	(937,310)	1,594,515
Cash and cash equivalents at beginning of period.	6,083,001	4,488,486
Cash and cash equivalents at end of period	\$ <u>5,145,691</u>	6,083,001

Great Wall Enterprise Co., Ltd.							
Profit Distribution							
2022							
Currency Unit: NT\$							
Balance as of January 1, 2022		2,221,938,450					
Add (Less):							
Welfare project revaluation variable	10,332,655						
Income after taxes for the year	2,193,060,982						
Earnings available for distribution		4,425,332,087					
Less (Add):							
Legal reserve	220,339,364						
Distribution items							
Shareholder dividends - cash	1 242 150 022						
(NT\$1.5 per share).	(NT\$1.5 per share). 1,342,150,833						
Undistributed earnings at the end of the		2 9 6 2 9 4 1 9 0 0					
period		2,862,841,890					

- Note: (1) Dividend distribution for the year shall not exceed the amount available for distribution in the period.
 - (2) Dividends will be distributed preferentially based on the after-tax benefits in 2022.